Subramaniam Pennathur1, Mamta Jaiswal2, Anuradha Vivekanandan-Giri3, Elizabeth A White3, Lynn Ang4, David M Raffel5, Melvyn Rubenfire6, Rodica Pop-Busui7. 1. Department of Internal Medicine and Molecular and Integrative Physiology, Division of Nephrology, University of Michigan, Ann Arbor, MI, United States. 2. Department of Neurology, University of Michigan, Ann Arbor, MI, United States. 3. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States. 4. Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, United States. 5. Department of Radiology, Division of Nuclear Medicine, University of Michigan, Ann Arbor, MI, United States. 6. Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, United States. 7. Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, United States. Electronic address: rpbusui@umich.edu.
Abstract
AIMS: To assess the role of oxidative stress in mediating adverse outcomes in metabolic syndrome (MetS) and resultant cardiovascular autonomic neuropathy (CAN), and to evaluate the effects of lifestyle interventions on measures of oxidative stress and CAN in subjects with MetS. METHODS: Pilot study in 25 non-diabetic subjects with MetS (age 49±10years, 76% females) participating in a 24-week lifestyle intervention (supervised aerobic exercise/Mediterranean diet), and 25 age-matched healthy controls. CAN was assessed by cardiovascular reflex tests, heart rate variability (HRV) and PET imaging with sympathetic analog [11C] meta-hydroxyephedrine ([11C]HED). Specific oxidative fingerprints were measured by liquid-chromatography/mass-spectrometry (LC/MS). RESULTS: At baseline, MetS subjects had significantly higher oxidative stress markers [3-nitrotyrosine (234±158 vs. 54±47μmol/mol tyrosine), ortho-tyrosine (59±38 vs. 18±10μmol/molphenylalanine, all P<0.0001], and impaired HRV at rest and during deep breathing (P=0.039 and P=0.021 respectively) compared to controls. Twenty-four-week lifestyle intervention significantly reduced all oxidative stress markers (all P<0.01) but did not change any of the CAN measures. CONCLUSIONS: Subjects with MetS present with signs of CAN and increased oxidative stress in the absence of diabetes. The 24-week lifestyle intervention was effective in ameliorating oxidative stress, but did not improve measures of CAN. Larger clinical trials with longer duration are required to confirm these findings.
AIMS: To assess the role of oxidative stress in mediating adverse outcomes in metabolic syndrome (MetS) and resultant cardiovascular autonomic neuropathy (CAN), and to evaluate the effects of lifestyle interventions on measures of oxidative stress and CAN in subjects with MetS. METHODS: Pilot study in 25 non-diabetic subjects with MetS (age 49±10years, 76% females) participating in a 24-week lifestyle intervention (supervised aerobic exercise/Mediterranean diet), and 25 age-matched healthy controls. CAN was assessed by cardiovascular reflex tests, heart rate variability (HRV) and PET imaging with sympathetic analog [11C] meta-hydroxyephedrine ([11C]HED). Specific oxidative fingerprints were measured by liquid-chromatography/mass-spectrometry (LC/MS). RESULTS: At baseline, MetS subjects had significantly higher oxidative stress markers [3-nitrotyrosine (234±158 vs. 54±47μmol/mol tyrosine), ortho-tyrosine (59±38 vs. 18±10μmol/molphenylalanine, all P<0.0001], and impaired HRV at rest and during deep breathing (P=0.039 and P=0.021 respectively) compared to controls. Twenty-four-week lifestyle intervention significantly reduced all oxidative stress markers (all P<0.01) but did not change any of the CAN measures. CONCLUSIONS: Subjects with MetS present with signs of CAN and increased oxidative stress in the absence of diabetes. The 24-week lifestyle intervention was effective in ameliorating oxidative stress, but did not improve measures of CAN. Larger clinical trials with longer duration are required to confirm these findings.
Authors: M J Stevens; F Dayanikli; D M Raffel; K C Allman; T Sandford; E L Feldman; D M Wieland; J Corbett; M Schwaiger Journal: J Am Coll Cardiol Date: 1998-06 Impact factor: 24.094
Authors: R Zamora-Ros; M Serafini; R Estruch; R M Lamuela-Raventós; M A Martínez-González; J Salas-Salvadó; M Fiol; J Lapetra; F Arós; M I Covas; C Andres-Lacueva Journal: Nutr Metab Cardiovasc Dis Date: 2013-02-26 Impact factor: 4.222
Authors: Brenda W C Bongaerts; Wolfgang Rathmann; Margit Heier; Bernd Kowall; Christian Herder; Doris Stöckl; Christa Meisinger; Dan Ziegler Journal: Diabetes Care Date: 2012-12-28 Impact factor: 19.112
Authors: Omar Asghar; Ioannis N Petropoulos; Uazman Alam; Wendy Jones; Maria Jeziorska; Andrew Marshall; Georgios Ponirakis; Hassan Fadavi; Andrew J M Boulton; Mitra Tavakoli; Rayaz A Malik Journal: Diabetes Care Date: 2014-06-26 Impact factor: 19.112
Authors: Scott M Williams; Aikaterini Eleftheriadou; Uazman Alam; Daniel J Cuthbertson; John P H Wilding Journal: Diabetes Ther Date: 2019-09-24 Impact factor: 2.945
Authors: Anna V Mathew; Lei Li; Jaeman Byun; Yanhong Guo; George Michailidis; Mamta Jaiswal; Y Eugene Chen; Rodica Pop-Busui; Subramaniam Pennathur Journal: Diabetes Care Date: 2018-09-10 Impact factor: 19.112